Everything below concerns BPC-157. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection of dry material |
| Solubility | Soluble in water | Polar aqueous solvent class |
| Typical storage | Minus 20 degrees Celsius, desiccated, dark | Applies to the lyophilized form |
| Purity assessment | Reversed-phase HPLC | Ultraviolet detection, area percent |
| Identity confirmation | Mass spectrometry | Measured mass compared with theoretical value |
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
== History == Orexigen Therapeutics submitted a New Drug Application (NDA) for the combination to the FDA in March 2010. Having paid a fee under the Prescription Drug User Fee Act, Orexigen was given a deadline for the FDA to approve or reject the drug of January 2011. In December 2010, an FDA Advisory Committee voted 13–7 to approve Contrave and 11–8 to conduct a post-marketing cardiovascular outcomes study. Subsequently, on 2 February 2011, the FDA rejected the drug, and it was decided that an extremely large-scale study of the long-term cardiovascular effects of Contrave would be needed before approval could be considered. It was ultimately approved in the United States in 2014. In December 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency endorsed the combination for licensure as an obesity medication when used alongside diet and exercise. Authorization was granted in March 2015. A review of Mysimba was completed by the CHMP in March 2025. In May 2015, Orexigen prematurely ended the trial that was intended to test whether naltrexone/bupropion increased the risk of major adverse cardiovascular events in obese patients with cardiovascular disease because an independent panel of experts said that the drug maker "inappropriately" compromised the trial by prematurely releasing interim data. The early data release reported a reduction in heart attacks, but that advantage was no longer observed when a more complete view of the data was analyzed.
CEEs are prodrugs of the active forms of the estrogens. Sodium estrone sulfate is a prodrug of estrone, which in turn is a prodrug of estradiol, while sodium equilin sulfate is a prodrug of equilin and then of 17β-dihydroequilin. As such, the major active estrogens with CEEs are estradiol and 17β-dihydroequilin, which have potent estrogenic activity and account for most of the effects of CEEs. The 17α-estrogens in CEEs such as 17α-estradiol and 17α-dihydroequilin have low estrogenicity and are thought to contribute minimally to its effects. There are many different steroids in natural CEE products like Premarin, as many as 230 compounds and including even androgens and progestogens, but only the estrogens are present in sufficient amounts to produce clinically-relevant effects. A dosage of 0.625 mg/day oral CEEs has been found to increase SHBG levels by 100%. For comparison, 1 mg/day oral estradiol increased SHBG levels by 45%, while 50 μg/day transdermal estradiol increased SHBG levels by 12%. Ethinylestradiol is more potent in its effects on liver protein synthesis than either CEEs or estradiol, with 10 μg/day oral ethinylestradiol having been found to be approximately equivalent to 1.25 mg/day CEEs.
==== Insurance ==== The transgender population has faced an increased burden of disease due to the lack of gender affirming coverage by insurance. Compared to the cisgender population, the transgender community has a lower insurance rate and faces obstacles with insurance (both private and public) denying coverage for many of their healthcare needs. According to the United States Transgender Survey (USTC), 20% of the transgender community reported insurance coverage for gender affirming care being partially covered or not being covered at all. Without insurance coverage, the transgender community is left with numerous out of pocket costs. The lack of insurance coverage denies these patients their healthcare needs and creates financial insecurity. These challenges with insurance create a decrease in healthcare outreach by the transgender community due to the costs. According to the United States Transgender Survey (USTS), 37.6% of the transgender community reported missing or avoiding preventative screenings and healthcare visits due to the costs This creates an increased burden of disease, and statistics show a higher rate of mental health conditions, poor physical health, and respiratory conditions, such as asthma. Besides the toll on this community's health and financial stability, insurers also refuse to change their records to reflect the true nature of the patient. Many health insurance companies have refused to change the individual's name and gender on their records. This creates another obstacle for this community to receive care while feeling accepted.
The World Health Organization and the US Centers for Disease Control and Prevention recommend that instrumentation used in such cases be immediately destroyed after use; short of destruction, it is recommended that heat and chemical decontamination be used in combination to process instruments that come in contact with high-infectivity tissues. Thermal depolymerization also destroys prions in infected organic and inorganic matter, since the process chemically attacks protein at the molecular level, although more effective and practical methods involve destruction by combinations of detergents and enzymes similar to biological washing powders.
Sources: en.wikipedia.org
== Regulation == Australia In Australia, dihydrocodeine is a 'pharmacist only' Schedule 3 drug, only when indicated for cough suppression, and compounded with one or more other therapeutically active substances not exceeding 15 mg dihydrocodeine per dose. Schedule 3 drugs, while still OTC, can only be dispensed after consultation with a pharmacist. It is a Schedule 4 (prescription only) drug when compounded with one or more other therapeutically active substances and not exceeding 100 mg dihydrocodeine per dose. Any Dihydrocodeine preparation not falling within Schedules 3 or 4, including single ingredient dihydrocodeine preparations, are categorised as Schedule 8 (controlled drugs), which can only be dispensed in accordance with the stricter requirements of the state or territory in which they are prescribed (and which vary between states and territories). Hong Kong In Hong Kong, dihydrocodeine is regulated under Schedule 1 of Hong Kong's Chapter 134 Dangerous Drugs Ordinance. It can only be used legally by health professionals and for university research purposes. A pharmacist can dispense Dihydrocodeine when furnished with a doctors prescription. Anyone who supplies the substance without a prescription can be fined $10000 (HKD). The penalty for trafficking or manufacturing the substance is a $5,000,000 (HKD) fine and life imprisonment. Possession of the substance for consumption, without a licence from the Department of Health, is illegal and carries a $1,000,000 (HKD) fine or 7 years imprisonment.
=== Europe === Dihydromorphine is regulated in the same fashion as morphine in Germany under the BtMG, Austrian SMG, and Swiss BtMG, where it is still used as an analgesic. The drug was invented in Germany in 1900 and marketed shortly thereafter. It is often used in Patient Controlled Analgesia units.
=== Synthesis and reactions === Several methods exist for the laboratory synthesis of dimethyl fumarate, with reported methods including alkene isomerization of dimethyl maleate, and Fischer esterification of fumaric acid. Dimethyl fumarate is an old compound used in industrial chemistry and can be purchased by the ton; as of 2012, one could purchase it for $1 to $50 per metric ton, with a two-ton minimum purchase. The compound undergoes electrohydrodimerization.
Sources: en.wikipedia.org
=== Occurrence in space === Nitriles are among the most abundant organic molecules in space, and more than ten distinct compounds have been unequivocally detected. Hydrogen cyanide was one of the first polyatomic species identified in space and occurs there relatively frequently and in substantial quantities. Other nitriles detected in space include acetonitrile and aminoacetonitrile, as well as butyronitrile, cyanoacetylene, and cyanopolyins containing two to five conjugated triple bonds. Hydrogen cyanide, cyanoacetylene, and cyanogen are present in the atmosphere of Saturn's moon Titan.
=== Bay of Bengal === India’s size and position means it has multiple roles in the southern route, both as a destination country and transit point for further destinations. The UNODC has estimated that 54% of the heroin in India is produced domestically, while 45% originates from Afghanistan. India is particularly vulnerable to the southern route due to its western border with Pakistan. Near this border, in the western Indian states of Punjab and Haryana, is where many of the heroin seizures occur. In 2012, 105 kg of drugs were seized, which had been trafficked from Pakistan along rail routes. In 2013 alone, the Indian Narcotics Control Bureau reported seizures totalling 4,609 kg. Data collected through seizures by various authorities has confirmed India as a transit country for Southeast Asia, West Africa and North America. Bangladesh also faces significant problems due to drug trade through the Indian Ocean and India. The country suffers from illicit drug use among its population, such as in Dhaka where there are an estimated 2.5 million people using drugs. India is a large provider of heroin to the Bangladeshi market, and it is trafficked over the western and eastern borders. However, it is unclear whether the heroin originates from Afghanistan or India, as this data has not been sufficiently collected. Both India and Bangladesh are becoming ever more dependent on maritime trade, with these states importing over US$52 million and US$447 million respectively.
Alberto E. Paniz-Mondolfi (born April 12, 1976) is a Venezuelan pathologist, epidemiologist, and molecular medicine researcher. Currently he is a pathologist and assistant professor in New York City and is affiliated with multiple hospitals in the area, including Mount Sinai Morningside and Mount Sinai West Hospitals and Mount Sinai Hospital. Also, he is the Academic Director and Founder of The Venezuelan Science Incubator (incubadorave.org), a group focused on infectious diseases research and awareness based in Venezuela.
Cloning – Dolly the sheep was the first mammal ever cloned from adult animal cells. The cloned sheep was, of course, genetically identical to the original adult sheep. This clone was created by taking cells from the udder of a six-year-old ewe and growing them in the lab. Gene therapy – a modified or healthy gene is inserted into the organism to replace a disease-causing gene. Commonly a virus that has been altered to carry human DNA is used to deliver the healthy gene to the targeted cells of the patient. This process was first used successfully in 1990 on a four-year-old patient who lacked an immune system due to a rare genetic disease called severe combined immunodeficiency (SCID).
Sources: en.wikipedia.org
Dry powder is commonly held at minus twenty degrees Celsius, desiccated and away from light. Cold storage slows degradation of the lyophilized material.
Mass spectrometry establishes the molecular mass, and reversed-phase chromatography reports purity. A certificate of analysis typically combines both results.
Solutions degrade faster than the dry powder, particularly at room temperature. Portioning into single-use aliquots and freezing reduces losses from repeated thawing.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.